Are there targeted therapies for cancers with IDH2 mutations?
Yes, targeted therapies have been developed for cancers harboring IDH2 mutations. One such drug is enasidenib (AG-221), an oral inhibitor specifically designed to target the mutant IDH2 enzyme. Enasidenib has shown promising results in clinical trials, leading to its approval for the treatment of relapsed or refractory AML with IDH2 mutations.
